TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema

Trial Profile

TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Macular degeneration; Uveitis
  • Focus Therapeutic Use
  • Acronyms TAHOE
  • Most Recent Events

    • 17 Mar 2015 Last checked against ClinicalTrials.gov record.
    • 10 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 16 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top